SALT LAKE CITY--(BUSINESS WIRE)--Tolero Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing treatments for oncology and hematologic diseases, today announced that its lead compound alvocidib has been chosen as one of the ‘Top 10 Most Interesting Oncology Projects to Watch’ for the Therapeutic Area Partnerships conference taking place in Boston, MA November 19-21, 2014. As a result of this designation, David Bearss, Ph.D., founder and CEO of Tolero Pharmaceuticals, will present a corporate overview and information about alvocidib, a multi cyclin-dependent kinase (CDK) small molecule inhibitor, at 1:00 PM on November 20, 2014.
Products selected as one of the Most Interesting Oncology Projects to Watch have met rigorous criteria, including unmet medical need, market potential, diversity of indications, strong science, partnering opportunities, and potential for new opportunities beyond initial indications.
Alvocidib is a potent small molecule inhibitor of cyclin-dependent kinases (CDKs) in development as a front-line combination therapy for acute myeloid leukemia (AML) and relapsed/refractory AML. CDKs are regulatory proteins that are critical to cellular replication and regulation of gene expression. Given the key role CDK de-regulation plays in unchecked cell division and growth, CDKs remain an attractive target for the treatment of various cancers.
Tolero Pharmaceuticals is a clinical stage biopharmaceutical company developing treatments to improve and extend the lives of patients with serious oncological and hematological diseases. Our diverse pipeline targets important biological drivers of blood disorders to treat leukemias and anemia as well as important targets of drug resistance and transcriptional control. For more information, visit www.toleropharma.com.